Results 1 to 10 of about 14,094 (223)

Safety of Semaglutide [PDF]

Frontiers in Endocrinology, 2021
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation. While GLP-1RAs effectively improve glycemic control and cause weight loss, potential safety concerns have arisen over the years.
Smits Mm, Van Raalte Daniel H, Smits Mark M   +2 more
exaly   +5 more sources

The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis

Contemporary Clinical Trials Communications, 2022
Aim: Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated for glycaemic management in adults with type 2 diabetes (T2D).
Yousef Alhindi, Amanda Avery
doaj   +1 more source

Semaglutide and pregnancy

International Journal of Gynecology & Obstetrics, 2023
SynopsisBoth use and cessation of semaglutide constitutes problems prior to and during pregnancy. More problems are expected with increasing use.
Kenneth Skov, Ida Nikoline Mandic, Kathinka Marie Nyborg   +2 more
openaire   +3 more sources

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China

Frontiers in Pharmacology, 2021
Introduction: Semaglutide is the first and only oral version of a glucagon-like peptide-1 analogue approved by the FDA for the treatment of type 2 diabetes (T2D). This research was designed to explore the appropriate price of once-weekly (OW) semaglutide
Shanshan Hu, Shanshan Hu, Xiaorong Su, Xun Deng, Xun Deng, Yong Wang, Yong Wang   +6 more
doaj   +1 more source

Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide

Pharmacology Research & Perspectives, 2022
Semaglutide is a glucagon‐like‐peptide‐1 (GLP‐1) analogue marketed for once‐weekly subcutaneous administration for type 2 diabetes mellitus. Like other long‐acting GLP‐1 analogues, semaglutide reduces gastric emptying and, potentially, alters the rate of
Emilie K. Langeskov, Kim Kristensen
doaj   +1 more source

Semaglutide reduces alcohol intake and relapse-like drinking in male and female ratsResearch in context

EBioMedicine, 2023
Summary: Background: Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD).
Cajsa Aranäs, Christian E. Edvardsson, Olesya T. Shevchouk, Qian Zhang, Sarah Witley, Sebastian Blid Sköldheden, Lindsay Zentveld, Daniel Vallöf, Maximilian Tufvesson-Alm, Elisabet Jerlhag   +9 more
doaj   +1 more source

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis

Frontiers in Pharmacology, 2021
Background: Cardio-renal profiles are available from cardiovascular outcome trials of glucagon-like peptide-1 receptor agonists (GLP-1 RAs).Methods: A comprehensive systematic review of Embase, Medline, Web of Knowledge, and CENTRAL databases was ...
Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chuanjun Zhuo, Chongguang Lin, Chunhua Zhou, Xiangyang Gao, Hailin Shao, Tao Fang, Hongjun Tian, Li Ding, Ming Liu   +11 more
doaj   +1 more source

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Cardiovascular Diabetology, 2020
Background Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations.
Mansoor Husain, Stephen C. Bain, Anders Gaarsdal Holst, Thomas Mark, Søren Rasmussen, Ildiko Lingvay   +5 more
doaj   +1 more source

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review

Clinical Epidemiology, 2022
Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Yang S, Deng W, Li J, Chen J
doaj  

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes

Biomedicines, 2021
Background: An unexpected increase in the rate of severe diabetic retinopathy was observed in the Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN)-6 clinical trial.
Rafael Simó, Patricia Bogdanov, Hugo Ramos, Jordi Huerta, Olga Simó-Servat, Cristina Hernández   +5 more
doaj   +1 more source